[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"early-psychosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:early-psychosis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,59,98,124,152],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100575602","digital-strategies-to-advance-help-seeking---aim-3-100575602",false,"NCT06774417","Digital Strategies to Advance Help-Seeking - Aim 3","Digital Strategies to Advance Help-Seeking in Youth at Clinical High Risk for Developing Psychosis","Inclusion Criteria:\n\n* Ages 12-29 years\n* Living within a 50-mile radius of a US based AMP-SCZ site\n* Able to complete the English language PQ-B on MHA's screening platform","ALL","12 Years","29 Years",{"count":20,"type":21},25000,"ESTIMATED","INTERVENTIONAL",[24],"NA","This proposal aims to establish a Digital Laboratory focused on advancing help-seeking and expediting treatment initiation in youth ages 12-29 who are at Clinical High-Risk (CHR) for developing psychosis. Leveraging the Health Action Process Approach (HAPA) model, this study will identify help-seeking subtypes in 25,000 youth who screen positive for psychosis-risk on Mental Health America's national online screening platform, iteratively develop and test theory and data-driven, personalized strategies to advance help-seeking using Micro-Randomized Trials and a Sequential Multiple Assignment Randomized Trial, identify the most accurate CHR screening threshold in an online environment, and link youth, when indicated, to local clinical care via AMP-SCZ, a NIH funded national network of CHR programs throughout the US. This academic-industry partnership aims to curate one of the largest datasets of youth with CHR, and to develop effective strategies to enhance early help-seeking, in a population where help-seeking is critical and a significant barrier to care.",[27,28,29],"Clinical High Risk","Early Psychosis","First Episode Psychosis","RECRUITING","2026-06-16",{"date":33,"type":34},"2026-06-18","ACTUAL",{"date":36,"type":34},"2026-02-02",{"date":38,"type":21},"2028-05-31",{"name":40,"class":41},"Columbia University","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":48,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":58,"locationsCount":42},"100575603","digital-strategies-to-advance-help-seeking-aim-1-and-2-100575603","NCT06774430","Digital Strategies to Advance Help-Seeking Aim 1 and 2",{"count":20,"type":21},"OBSERVATIONAL","This proposal aims to establish a Digital Laboratory focused on advancing help-seeking and expediting treatment initiation in youth ages 12-29 who are at Clinical High-Risk (CHR) for developing psychosis. Leveraging the Health Action Process Approach (HAPA) model, this study will identify help-seeking subtypes in 25,000 youth who screen positive for psychosis-risk on Mental Health America's national online screening platform, iteratively develop and test theory and data-driven, personalized strategies to advance help-seeking using Micro-Randomized Trials and a Sequential Multiple Assignment Randomized Trial, identify the most accurate CHR screening threshold in an online environment, and link youth, when indicated, to local clinical care via Accelerating Medicines Partnership - Schizophrenia (AMP-SCZ), a NIH funded national network of CHR programs throughout the US. This academic-industry partnership aims to curate one of the largest datasets of youth with CHR, and to develop effective strategies to enhance early help-seeking, in a population where help-seeking is critical and a significant barrier to care.",[27,28,29],"2026-04-30",{"date":54,"type":34},"2026-05-05",{"date":56,"type":34},"2025-04-07",{"date":38,"type":21},{"name":40,"class":41},{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":16,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":70,"conditions":71,"keywords":78,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":5},"100572985","biomarkersbiotypes-course-of-early-psychosis-and-specialty-services-100572985","NCT06740383","Biomarkers\u002FBiotypes, Course of Early Psychosis and Specialty Services","BICEPS","Inclusion Criteria:\n\n* Males and females, all races and ethnicities\n* 18-40 y\u002Fo\n* Meet DSM-5 criteria for a psychotic disorder, i.e. schizophrenia, schizophreniform, schizoaffective disorder, or bipolar I disorder or major depression with psychotic features, delusional disorder or psychosis N.O.S.\n* Able to read, speak, and understand English\n* Able and willing to provide written informed consent, and willing to commit to the study protocol\n* Illness duration from psychosis onset less than or equal to 4 years\n* At baseline only: receiving both psychopharmacology and psychotherapy\n\nExclusion Criteria:\n\n* Estimated premorbid intellectual ability \\\u003C70 (WRAT-4, Word Reading subtest, age-corrected standardized score)\n* Neurological or medical disorder that may affect brain function (seizure disorder, traumatic brain injury with a loss of consciousness greater than or equal to 30 min, history of stroke, AIDS, etc.)\n* Psychoses secondary to substance use i.e., Comorbid DSM-5 diagnosis of alcohol or substance use disorders that may explain the diagnosis of psychotic disorders (individuals with cannabis use disorders unrelated to psychosis onset will be allowed. Participants encouraged to abstain from substances for 24 hours prior to lab visits)\n\nMRI-Specific Exclusion Criteria:\n\n* Pregnant women\n* Presence of ferromagnetic objects in body\n* Weight or body size exceeding scanner capacity (\\>300 lbs)\n* Claustrophobia","18 Years","40 Years",{"count":69,"type":21},320,"The Biomarkers\u002FBiotypes, Course of Early Psychosis and Specialty Services (BICEPS) study aims to understand the early stages of psychotic disorders like Schizophrenia, Schizoaffective Disorder, and Bipolar I Disorder. It involves gathering mental health information, brain scans (MRI), eye movement patterns (Eye-Tracking), and brain electrical waves (EEG) data from individuals who have experienced these disorders in recent years. Participants will be involved for about a year, with four visits over this period. Screening procedures, lasting approximately 3 hours, include tests for drug use, a pregnancy test for eligible women, clinical interviews about feelings and experiences, psychiatric and family history interviews, and a medical history review. Research procedures for eligible participants include DNA collection, a neuropsychological test battery, EEG, eye-tracking, and MRI. These procedures will help researchers understand brain function, genetics, and cognitive abilities related to psychotic disorders. Follow-up visits at 1-month, 6-month, and 12-month intervals involve modified clinical interviews and repeating neuropsychological tests to track changes over time. Participants may opt to provide DNA samples for genetic analysis, undergo various cognitive tests, EEG to record brain waves, eye-tracking to monitor eye movements, and MRI scans to visualize brain structure. Follow-up visits at regular intervals will help researchers track changes in symptoms and cognitive function. This study provides comprehensive insight into the onset and progression of psychotic disorders and offers valuable information for patients, families, and healthcare providers involved in managing these conditions. Our goal is to better understand whether a combination of biological markers and different types of people (BT1, BT2, BT3) can help us predict how well individuals with early psychosis respond to specialized care. We expect that those in BT3 will have the best outcomes, BT2 will have intermediate outcomes, and BT1 will have the poorest outcomes. Even though BT1 and BT2 might start with similar cognitive issues, their biology might lead to different responses to treatment. This research can help us understand which treatments work best for different people with early psychosis.",[72,73,74,75,76,77,28],"Schizophrenia Spectrum and Other Psychotic Disorders","Schizophrenia","Delusional Disorder","Bipolar 1 Disorder","Schizoaffective Disorder","Psychosis Not Otherwise Specified",[79,80,81,82,83,84,85,86,87,88],"schizophrenia","bipolar disorder","schizoaffective disorder","schizophreniform","major depression","psychosis","delusional disorder","Biotypes","Biomarkers","coordinated specialty care","2026-03-06",{"date":91,"type":34},"2026-03-10",{"date":93,"type":34},"2023-01-01",{"date":95,"type":21},"2027-06-30",{"name":97,"class":41},"Beth Israel Deaconess Medical Center",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":105,"sex":16,"minAge":66,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100627279","perception-and-integration-of-sensory-information-in-the-early-stages-of-psychosis-100627279","NCT07446569","Perception and Integration of Sensory Information in the Early Stages of Psychosis","PRIOR-ePSY","Inclusion criteria:\n\nAll groups:\n\n* Age between 18 and 30 years\n* Normal or corrected-to-normal visual acuity\n* Affiliated with or dependent on a social security health insurance plan\n* Provided informed consent and co-signed the study consent form with the investigator\n* Proficient in French\n\nControl group (TEM) specific criteria:\n\n* No current psychiatric disorder (DSM-IV Axis I), except anxiety disorders\n* No lifetime history of (hypo)manic episodes or psychotic disorders\n* No first-degree family history of schizophrenia spectrum disorders\n* No regular use (more than one month continuously) in the past 6 months of the following medications: benzodiazepines, hypnotics, antidepressants, antipsychotics, mood stabilizers, or psychostimulants\n\nClinical High-Risk (CHR) group specific criteria:\n\n-Meet CHR criteria according to CAARMS: Attenuated positive symptoms (APS) below clinical threshold in intensity or frequency OR Brief Limited Intermittent Psychotic Symptoms (SPLI) OR Genetic Risk\n\nFirst-Episode Psychosis (PEP) group specific criteria:\n\n-Meet PEP criteria according to CAARMS (psychosis threshold reached)\n\nExclusion criteria:\n\n* Pregnant, postpartum, or breastfeeding women\n* Individuals deprived of liberty by judicial or administrative decision\n* Individuals in a life-threatening emergency\n* Adults under legal protection measures\n* Adults unable to provide consent and not under legal protection\n* Impairment that makes participation in the study or understanding of information difficult or impossible\n* Alcohol dependence (AUDIT score ≥12 for men, ≥11 for women)\n* Current substance use disorder (DAST score \\>6)\n* Cannabis use disorder (CUDIT-R score ≥13)\n* History of neurological disorders, including progressive neurological disease\n* Progressive retinal disease\n* Chronic glaucoma\n* Ophthalmologic conditions affecting visual acuity\n* Current eye infection\n* Hearing disorders affecting auditory acuity\n\nCriteria incompatible with the electroretinographic device:\n\n* Presence of photosensitive epilepsy\n* Allergy to components of the electrode gel\n* Behavioral problems causing extreme agitation or aggression\n* Eye or surrounding tissue lesions that may come into contact with the device",true,"30 Years",{"count":108,"type":21},294,[24],"The goal of this observational study is to investigate the early sensory system in clinical high risk (CHR), first episode psychosis (FEP) individuals and heathly controls. The main questions it aims to answer are:\n\n* Can anomalies in visual and auditory sensory processing serve as early markers of psychosis risk?\n* How are these sensory anomalies related to clinical symptom severity and emotional recognition deficits?\n\nResearchers will compare CHR and PEP participants to healthy controls to see if sensory processing differences can help identify individuals at higher risk of developing psychosis.\n\nParticipants will:\n\n* Complete behavioral tasks evaluating visual processing (contrast sensitivity, contour integration, facial emotion recognition, visual inference using Necker cubes) and auditory processing (tone-matching, auditory emotion recognition). A temporal perception component will also be assessed within the auditory and emotion recognition tasks, rather than as a separate task.\n* Undergo electrophysiological assessments of retinal function using flash stimulation to record retinal potentials (a-wave, b-wave, phNR, oscillatory potentials).\n* Provide demographic, clinical, and neuropsychological data during study visits.\n* For CHR participants, attend follow-up visits up to 6 months post initial assessments to evaluate psychotic symptom progression.",[28,112],"Schizophrenia Prodromal","NOT_YET_RECRUITING","2026-02-26",{"date":116,"type":34},"2026-03-03",{"date":118,"type":21},"2026-04",{"date":120,"type":21},"2028-11",{"name":122,"class":41},"Centre Psychothérapique de Nancy",4,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":66,"maxAge":106,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":135,"conditions":136,"keywords":138,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":42},"100625074","brave-program-to-improve-safety-and-reduce-violence-risk-in-early-psychosis-100625074","NCT07417904","BRAVE Program to Improve Safety and Reduce Violence Risk in Early Psychosis","Young Adults and Violent Behavior During Early Psychosis (Aim 3)","BRAVE","Inclusion Criteria:\n\n* Young adults aged 18-30 years\n* Diagnosis of early psychosis\n* Currently receiving outpatient care through an early psychosis clinic\n* Psychiatrically stable and deemed appropriate for participation by a treating clinician\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* Unable to provide informed consent\n* Not fluent in English\n* History of antisocial behavior, as assessed at baseline\n* Immediate risk requiring a higher level of care",{"count":133,"type":21},30,[24],"This study evaluates the feasibility and acceptability of BRAVE, a manualized cognitive behavioral therapy (CBT)-based intervention designed to address dynamic risk factors for violence among young adults with early psychosis. Using a stepped-wedge randomized design, all participants will receive treatment as usual followed by the BRAVE intervention. The study will also explore changes in violence-related behaviors and treatment engagement over time.",[137,28],"Violence Risk",[139,140,141,142],"early psychosis","violence risk","aggression","cognitive behavioral therapy","2026-02-10",{"date":145,"type":34},"2026-02-18",{"date":147,"type":21},"2026-02-16",{"date":149,"type":21},"2026-08",{"name":151,"class":41},"Howard University",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":16,"minAge":159,"maxAge":106,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":175},"100394066","phase-3-effects-of-cannabidiol-cbd-versus-placebo-as-an-adjunct-to-treatment-in-early-psychosis-100394066","NCT04411225","Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis","Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis: Understanding the Mechanism and Mediators of Action","Inclusion Criteria:\n\n* First episode psychosis (onset within the last 2 years) or attenuated psychosis syndrome (APS), stabilized with treatment for at least 8 weeks prior to initiating the trial consistent with the FDA-NIMH-MATRICS guidelines for clinical trial design for clinical enhancing drugs:\n* Clinically stable and in a nonacute phase of their illness for at least 2 months, First episode psychosis participants will have been maintained on current antipsychotic for at least 6 weeks, with no change in antipsychotic dose for the previous 4 weeks while APS participants will be on the same treatment regimen (psychosocial or pharmacologic) for 4 weeks,\n* Exhibit no more than moderate levels of positive symptoms (defined by ratings of ≤ 4) on PANSS items P1 (delusions), P2 (conceptual disorganization), P3 (hallucinatory behavior), P5 (grandiosity), P6 (suspiciousness), and G8 (unusual thought content),\n* No more than a minimal level of depressive symptoms as assessed by the Calgary Depression Scale for Schizophrenia (CDSS)\n* Acceptable diagnoses will include APS, Psychosis NOS, Schizophreniform, Schizophrenia, and Schizoaffective per the Structured Clinical Interview for DSM-V.\n\nExclusion Criteria:\n\n* Concomitant medical or neurological illness;\n* Significant head injury;\n* Impaired intellectual functioning IQ\\\u003C80; however those with an IQ i the 75-79 range will be include if WRAT reading \\> 85 suggesting higher premorbid IQ.\n* High suicidal risk assessed by the The Columbia-Suicide Severity Rating Scale (C-SSRS)42\n* Pregnant women and those who do not agree to avoid becoming pregnant\n* Patients requiring treatment with Azelastine, Azelastine; Fluticasone, Dronabinol, Valproic Acid, or Divalproex Sodium","16 Years",{"count":161,"type":21},120,[163],"PHASE3","This is an outpatient, single center, between-group, double blind, placebo controlled design. Approximately 120 adolescents and adult patients will be randomized to either have their treatment augmented with Cannabidiol Oral Solution (CBD) or with a matching CBD placebo for 8 weeks. The study will examine CBD as an augmentation strategy in early psychosis. It is hypothesized that CBD will improve symptoms, neurocognition, markers of inflammation and eating behaviors. Importantly, moderators and mediators of the CBD effects will be explored.",[28],"2026-01-07",{"date":168,"type":34},"2026-01-08",{"date":170,"type":34},"2022-06-01",{"date":172,"type":21},"2026-12",{"name":174,"class":41},"University of California, San Diego",2]